Shares Outstanding 19.9 M
Institutional Ownership 36.24%
Number of Floating Shares 14.3 M
Trial is solid and OS is the key here. It works.
Hold for buyout between 25.00 and 30.00
I like the patent and technology that will most likely reinvent the current panel of oncology drugs, but 700.00 is just crazy.
CELG will recognize the value of this patent. They bought Abraxis and they had a similar technology. CLRB's technology will trump that of Abraxane. I don't think CELG will want to let someone else take their market share. Logical buyout play.
That patent may be worth billions. A entire platform of previously successful drugs may be used. Will be discussed at ASCO conference this weekend. Then you have SNMMI the following weekend.
Jun 11, 2016 - Jun 15, 2016 - SNMMI 2016 Annual Meeting
San Diego Convention Center
Headquarter Hotel: Hilton San Diego Bayfront
This may see the low teens by then. Positioned for a major stream of big events.